Induction of chondrogenesis with a RANKL-binding peptide, WP9QY, in vitro and in vivo in a rabbit model

• Published in: Biochemical and biophysical research communications Vol. 602; pp. 98 - 104
• Main Authors: Furuya, Yuriko, Mera, Hisashi, Itokazu, Maki, Terai, Shozaburo, Nakamura, Hiroaki, Wakitani, Shigeyuki, Yasuda, Hisataka
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 30.04.2022
• Subjects: Animals; Articular cartilage; Cartilage, Articular - metabolism; Cell Differentiation; Cells, Cultured; Chondrocytes - metabolism; Chondrogenesis; Osteoclasts - metabolism; Osteogenesis; Peptides - metabolism; Peptides - pharmacology; Rabbits; RANKL; RANKL-Binding peptide; Transforming Growth Factor beta3 - metabolism; RANKL; W9; hMSCs; OPG; IGFBP2; IGF; PFA; sGAGs; FGF2; RANKL-Binding peptide; ACAN; 2D; COL2A1; Articular cartilage; TGF-β; SOX9; Chondrogenesis; RANKL-Ab
• ISSN: 0006-291X; 1090-2104
• DOI: 10.1016/j.bbrc.2022.03.019

WP9QY (W9) is a receptor activator of nuclear factor-κB ligand (RANKL)-binding peptide that inhibits osteoclastogenesis by blunting the RANKL-RANK interaction, and also increases osteoblastogenesis via RANKL reverse signaling. W9 has dual effects on osteoclasts and osteoblasts; however, it is unknown whether the peptide has an effect on chondrocytes. Here, we report that W9 induces proliferation and differentiation of chondrocytes in vitro and repairs full-thickness articular cartilage defects in vivo. W9 stimulated chondrocyte differentiation in a two-dimensional (2D) culture of human mesenchymal stem cells (hMSCs), and transforming growth factor β3 (TGF-β3) showed synergistic effects with W9 on chondrogenesis. W9 enlarged the size of 3D pellet cultures of hMSCs and produced chondrocyte-specific matrices, especially in combined treatment with TGF-β3. The peptide also stimulated proliferation of hMSCs with induction of expression of chondrogenesis-related genes. Several RANKL inhibitors had no effect on chondrocytic differentiation. RANKL-knockdown experiments showed that W9 did not induce chondrogenesis through RANKL, but did induce osteoblastogenesis through RANKL. Intraarticular injection of W9 resulted in significant repair of full-thickness articular cartilage defects in rabbits. Taken together, these results suggest that W9 ameliorates the articular cartilage defects by increasing the volume of cartilaginous matrices with accompanying induction of proliferation and differentiation of chondrocytes via mechanisms independent of RANKL inhibition and RANKL reverse signaling. Since no pharmaceuticals are clinically available for treatment of cartilage damage such as osteoarthritis, our findings demonstrate the potential of W9 to address the unmet medical needs. •Accumulation of cartilaginous matrices in chondrocytes with WP9QY peptide.•Synergy between WP9QY and TGF-β3 in chondrogenesis.•Unknown mechanisms independent of RANKL inhibition and RANKL reverse signaling.•Potential to address unmet medical needs for cartilage damage such as osteoarthritis.•Important clues for understanding regulation of cartilage regeneration.